Director/PDMR Shareholding
August 22, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of transaction by person discharging managerial responsibilities
| 1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA") | ||
| a) | Name | Flemming Ornskov | |
| 2. | Reason for the notification | ||
| a) | Position / status | Chief Executive Officer - PDMR | |
| b) | Initial notification / amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Shire plc | |
| b) | LEI | 54930005LQRLI2UXRQ59 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares") | |
| Identification code | ISIN: JE00B2QKY057 | ||
| b) | Nature of the transaction | Acquisition of Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £36.6493 | 8,400 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | |
| e) | Date of the transaction | August 22, 2017 | |
| f) | Place of the transaction | London Stock Exchange | |
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Ian Karp | [email protected] | +1 781 482 9018 |
| Robert Coates | [email protected] | +44 1256 894874 |
| Media | ||
| Lisa Adler | [email protected] | +1 617 588 8607 |
| Debbi Ford | [email protected] | +1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.


China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 



